ADCT
ADC Therapeutics SA
$1.28
-0.07 (-5.19%)
At close · Jul 8
Market Cap
$162.80M
Shares
127,191,158
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$81.36M
+14.9%
FY2025
Net Income
-$142.6M
+9.6%
FY2025
Gross Margin
92.87%
+1.3pp
FY2025
Operating Margin
-149.34%
+35.1pp
FY2025
Diluted EPS
-$1.12
+30.9%
FY2025
Operating Cash Flow
-$141.17M
-14%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| $79.18M | $81.36M | $70.84M | $69.56M | |
| — | $5.8M | $5.95M | $2.53M | |
| — | $75.56M | $64.89M | $67.03M | |
| — | 92.87% | 91.6% | 96.36% | |
| $94.95M | $104.01M | $109.63M | $127.13M | |
| $45.53M | $43.37M | $44.02M | $57.46M | |
| $36.5M | $36.56M | $41.89M | $48.42M | |
| $197.46M | $202.86M | $201.49M | $235.54M | |
| -$118.28M | -$121.5M | -$130.65M | -$165.99M | |
| — | -149.34% | -184.44% | -238.63% | |
| $51.75M | $51.63M | $50.21M | $46.33M | |
| $8.75M | $8.81M | $12.27M | $10.54M | |
| -$17.86M | -$20.11M | -$25.48M | -$29.43M | |
| — | $0 | -$1.54M | -$5.53M | |
| -$136.14M | -$141.61M | -$156.14M | -$195.42M | |
| $850K | $1.02M | $166K | $39.11M | |
| -$136.97M | -$142.6M | -$157.8M | -$240.1M | |
| — | -175.28% | -222.76% | -345.18% | |
| -$136.7M | -$141.72M | -$159.18M | -$241.97M | |
| USD/shares | — | -$1.12 | -$1.62 | -$2.94 |
| USD/shares | — | -$1.12 | -$1.62 | -$2.94 |
| shares | — | 127.07M | 97.16M | 81.71M |
| shares | — | 127.07M | 97.16M | 81.71M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Reportable Segment | $81,357,000 | $70,837,000 | $69,558,000 |
By Geography (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| United States | $73,551,000 | $69,280,000 | $69,060,000 | $74,908,000 |
| EMEA | $7,806,000 | $1,557,000 | $498,000 | $105,000,000 |
| Japan | — | — | — | $30,000,000 |
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Product | $73,551,000 | $69,280,000 | $69,060,000 | $74,908,000 |
| License and Royalty Revenue | $7,806,000 | $1,557,000 | — | — |
| License Revenues | $5,000,000 | $0 | — | $135,000,000 |
| Royalty Revenue | $2,806,000 | $1,557,000 | $498,000 | $0 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Reportable Segment | -$121,499,000 | -$130,654,000 | -$165,986,000 |
Operating Margin by Segment (%)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Reportable Segment | -149.3% | -184.4% | -238.6% |